Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

https://www.acpjournals.org/doi/10.7326/M20-1550

This reports the first pharmacokinetic data of lopinavir and ritonavir in patients hospitalized with COVID-19. Lopinavir trough levels were approximately 2-fold higher in COVID  population than in patients with HIV receiving the same dose (7.1 μg/mL). Despite the approximately 2-fold higher
lopinavir trough concentrations in  sample of patients with COVID-19 compared with patients with HIV, approximately 60- to 120-fold higher concentrations are required to reach the assumed EC50 at trough levels, making effective treatment of COVID-19 with lopinavir and ritonavir at the currently used doses unlikely.

Tags: